Carlos Augusto Monteiro, the epidemiologist who created the concept of "ultra-processed" foods, has questioned an initiative ...

Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug in major emerging markets like India, Brazil and ...

Novo Nordisk ( NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its ...

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...

A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...

Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.

Novo Nordisk A/S (NYSE: NVO) has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...

Walgreens jumps as Sycamore agrees to $11.45 a share purchase Sycamore Partners agreed to acquire Walgreens Boots (WBA) in a ...

Blackstone, BlackRock, Apollo Global Management, Novo Nordisk A/S, Welltower, Prologis, and Venture Global are the seven Growth stocks to watch today, according to MarketBeat’s stock screener tool.